DBV Technologies will participate in the upcoming ACAAI 2024 conference | 18.10.24

Châtillon, France, October 18, 2024

DBV Technologies is participating in the upcoming ACAAI 2024 conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its upcoming participation in the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) , October 24 – 28.^e2024 in Boston, Massachusetts.

This year’s meeting will feature a “Product Theater.” What defines optimal treatment for peanut allergy? During this panel discussion, Drs. Shahzad Mustafa, Edwin Kim, Julia Upton and CEO of Food Allergy Research and Education (FAACT), Eleanor Garrow-Holding, will engage in a discussion on the characteristics of optimal treatment for peanut allergy, focusing on efficacy goals , safety and practical. The Product Theater is scheduled for Saturday, October 26^efrom 11:35 AM to 1:00 PM EDT.

DBV also sponsors the 33^RD Annual FIT Bowl, a game show-type competition that tests the allergy, asthma and immunology knowledge of participating teams from training programs across the country. The competition will take place on Saturday, October 26^efrom 5:45 PM to 7:45 PM EDT. In addition, DBV will be a member of the ACAAI Benefactor Level Corporate Council in 2024. The company will also have a booth at the ACAAI Exhibit Hall from Friday, October 25^e – Monday October 28^e.

“We are very pleased to join our food allergy colleagues at ACAAI again this year, especially after recently completing enrollment for VITESSE in children 4 – 7 years old.” said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies. “Our global collaboration has enabled us to reach this crucial milestone. DBV continues to advance our regulatory progress with the Viaskin^® peanut patch in 1-3 year olds and 4-7 year olds. We look forward to opportunities at the ACAAI to further discuss the unmet medical need in peanut allergy and explore ways we can work together across the community to support advances in food allergy.”

DBV presentation:

Product Theater (non-CME)
“What Defines Optimal Treatment for Peanut Allergy?” with participation of Dr. Shahzad Mustafa, Rochester Regional Health, Dr. Edwin Kim, UNC Pediatric Allergy & Immunology, Dr. Julia Upton, MPH, The Hospital for Sick Children and Eleanor Garrow-Holding, CEO of Food Allergy and Anaphylaxis Connection Team (FAACT).

• Presentation date: Saturday October 26^e
• Presentation time: 11:35 AM to 1:00 PM EDT
• Session/Location: HCC, Level 2, Exhibition Halls C & D, Product Theater #2

The Viaskin® Peanut Patch is the company’s lead product candidate, designed to reduce the risk of allergic reactions due to accidental exposure to peanuts. An experimental, non-invasive, once-daily epicutaneous patch, the Viaskin Peanut patch, attempts to deliver microgram amounts of peanut antigen to re-educate the immune system. The safety and effectiveness of the Viaskin Peanut patch have not yet been established by the U.S. Food and Drug Administration or the European Medicines Agency.

About DBV technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunological disorders with significant unmet medical need. DBV is currently focused on exploring the use of its patented Viaskin® patch technology to address food allergies, which are caused by a hypersensitive immune response and are characterized by a range of symptoms ranging in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Using epicutaneous immunotherapy (EPIT™), the Viaskin® patch is designed to introduce microgram amounts of a biologically active compound into the immune system through intact skin. EPIT is a new class of non-invasive treatments that aim to modify an individual’s underlying allergy by retraining the immune system to become desensitized to the allergen by utilizing the immune-tolerant properties of the skin. DBV is committed to transforming care for food allergic people. The company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut-allergic toddlers (1 to 3 years) and children (4 to 7 years).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one ordinary share) are traded on the Nasdaq Capital Select Market (Ticker: DBVT).

For more information, visit www.dbv-technologies.com and follow us on X (formerly Twitter) and LinkedIn.

Forward-Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding DBV’s financial condition, cash runway forecast, the therapeutic potential of Viaskin® Peanut patch and EPIT™, DBV’s anticipated clinical trial designs, planned regulatory and clinical efforts of DBV. including timing and results of communications with regulatory authorities, the ability of all DBV product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve significant risks and uncertainties. At this time, DBV’s product candidates have not been approved for sale in any country. Factors that could cause actual results to differ materially from those described or projected herein include uncertainties generally associated with research and development, clinical trials and related regulatory reviews and approvals, and the ability of DBV to successfully implement its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements contained in this press release can be found in the DBV filing with the French Autorité des Marchés Financiers (“AMF “) registration dossiers submitted. , DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 7, 2024, and future filings and reports prepared with the AMF and SEC by DBV. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Except as required by applicable law, DBV TECHNOLOGIES assumes no obligation to update or revise the information contained in this press release.

Viaskin is a registered trademark and EPIT is a trademark of DBV Technologies.

Contact person for investors
Katie Matthews
+1 (857) 529-2363
[email protected]

Media contact
Angela Marcucci
+1 646-842-2393
[email protected]